tradingkey.logo

BUZZ-Emergent up on gaining commercial rights for Hikma's opioid overdose treatment

ReutersJan 14, 2025 1:48 PM

Shares of drugmaker Emergent BioSolutions EBS.N rise ~2.9% to $9.68 premarket

Emergent says it gained exclusive commercial rights to Hikma Pharmaceuticals' HIK.L opioid reversal nasal spray, Kloxxado

Kloxxado rapidly reverses or blocks the effects of opioids, restoring normal respiration, especially when given within minutes of the first signs of an overdose

Under the terms of the agreement, Hikma will continue to manufacture the nasal spray, while Emergent will handle distribution

Up to last close, EBS up more than four-fold in the last 12 months

(Reporting by Christy Santhosh)

((Christy.Santhosh@thomsonreuters.com))

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI